| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000036275 |
| Receipt No. | R000041316 |
| Scientific Title | Protective and ameliorative effects of the extracts of Cistanche tubulosa on locomotive syndrome. |
| Date of disclosure of the study information | 2019/04/01 |
| Last modified on | 2020/03/12 (Ver. 2) |
| Basic information | ||
| Public title | Protective and ameliorative effects of the extracts of Cistanche tubulosa on locomotive syndrome. | |
| Acronym | Protective and ameliorative effects of the extracts of Cistanche tubulosa on locomotive syndrome. | |
| Scientific Title | Protective and ameliorative effects of the extracts of Cistanche tubulosa on locomotive syndrome. | |
| Scientific Title:Acronym | Protective and ameliorative effects of the extracts of Cistanche tubulosa on locomotive syndrome. | |
| Region |
|
|
| Condition | ||
| Condition | Subjects having the risk of locomotive syndrome | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | This study aims to investigate effects of the extract of Cistanche tubulosa on locomotive syndrome. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Function of locomotive systems |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | Numbered container method |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Tretament test drug: Intake of powder containing the extracts of Cistanche tubulosa (1800 mg/bag), one bag per day, for 12 weeks. | |
| Interventions/Control_2 | Treatment placebo:Intake of powder without the extract, one bag per day, for 12 weeks. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Subjects who checked at least one item among "Loco check" between age 40 to 80 years old, who volunteers to attend this clinical study.
|
|||
| Key exclusion criteria | Subjects under 20 years old, pregnant or lactating. Subjects during medication such as muscle relaxants, osteoporosis drugs, rheumatoid arthritis drugs.
Subjects having mental illnesses. Subjects judged being inappropriate by other reasons. |
|||
| Target sample size | 20 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | University of Toyama | ||||||
| Division name | Division of Neuromedical Science, Institute of Natural Medicine | ||||||
| Zip code | 930-0194 | ||||||
| Address | 2630 Sugitani, Toyama, 930-0194, JAPAN | ||||||
| TEL | 076-434-7646 | ||||||
| chihiro@inm.u-toyama.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | University of Toyama | ||||||
| Division name | Division of Neuromedical Science, Institute of Natural Medicine | ||||||
| Zip code | 930-0194 | ||||||
| Address | 2630 Sugitani, Toyama, 930-0194, JAPAN | ||||||
| TEL | 076-434-7646 | ||||||
| Homepage URL | |||||||
| chihiro@inm.u-toyama.ac.jp | |||||||
| Sponsor | |
| Institute | Division of Neuromedical Science, Institute of Natural Medicine, University of Toyama |
| Institute | |
| Department | |
| Funding Source | |
| Organization | MEXT |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | IRB center, Sugitani campus, University of Toyama |
| Address | 2630 Sugitani, Toyama, 930-0194, JAPAN |
| Tel | 076-434-7145 |
| yuka@adm.u-toyama.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 国立大学法人 富山大学 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 20 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041316 |